Please login to the form below

Not currently logged in

Sanofi-aventis to buy Chattem for $1.9bn

Sanofi-aventis is to acquire US consumer healthcare company Chattem in a deal valued at around $1.9bn

Sanofi-aventis is to acquire US consumer healthcare company Chattem in a deal valued at around $1.9bn – equal to £93.50 a share in cash, which is 34 per cent above Chattem's closing price on December 18.

The purchase will create the world's fifth-largest consumer health company by revenue and is in line with CEO Chris Viehbacher's strategy to broaden sanofi-aventis' business.

Viehbacher said the acquisition "will be a significant milestone in sanofi-aventis' transformation strategy" to convert prescription medicines to over-the-counter (OTC) products. He added "we've never had a consumer healthcare presence in the US, Chattem is the ideal entry for us into this market."

The French drugmaker plans to convert Allegra (fexofenadine) to an OTC product. The antihistamine, which has faced generic competition since 2005, saw branded sales of €688m ($985m) last year.

Viehbacher explained "we've had significant interest from the major actors in the OTC world to switch Allegra. There's a huge appetite for a switch like this."

The companies indicated that the transaction will close in the first quarter of 2010.

22nd December 2009


COVID-19 Updates and Daily News

Featured jobs


Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...